Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions
April 22, 2016
This low rate of target lesion revascularization translated into meaningful clinical improvement for the majority of patients, with both the average walking distance and average walking speed more than doubling following Zilver PTX stent implantation, and being sustained to two years. In addition there was a very good safety profile, and a very low rate of stent fractures.
"These interim data suggest this device is safe and efficacious for the treatment of SFA lesions," said William A. Gray, M.D., FSCAI, who presented the study data and is associate professor of clinical medicine and director of endovascular services at Columbia University Medical Center/New York Presbyterian Hospital. "Prior attempts to demonstrate drug-eluting stent effectiveness using sirolimus or its analogues have fallen short, but the use of a paclitaxel-coated, non-polymeric stent appears to have improved the outcomes for patients who received this study stent. If these results are confirmed in the separate randomized study using the same device, it will be welcome news to patients who suffer from this disease."
Dr. Gray reports no conflicts of interest related to this study. He will present the study "Two-year interim results from the single-arm clinical study of the Zilver?� PTX?� drug-eluting peripheral stent" during the Main Session on Friday, May 7, at 11:30 a.m. (Pacific Time).
SOURCE SCAI